4th ISIRV-AVG Conference Speaker: Dr. Carol Epstein, MediVector CMO, to speak on ‘The Clinical and Anti-Influenza Virus Effects of Favipiravir, a Novel Anti-RNA Virus, Anti-Influenza Agent’ http://www.isirv.org/site/index.php/special-interest-groups/antiviral-group-home/9-events/233-4th-isirv-avg-conference
About Andrew Cann
This author has yet to write their bio.Meanwhile lets just say that we are proud Andrew Cann contributed a whooping 4 entries.
Entries by Andrew Cann
XVII International Symposium on Respiratory Viral Infections Speakers: Carol Epstein, MediVector CMO, to speak on ‘Favipiravir (T705) Developments’
Boston, February 17, 2015 -More than 2,000 patients enrolled in the Americas, Europe, Australia, New Zealand and South Africa- MediVector, Inc. today announced it has successfully completed enrollment in two FAVOR favipiravir Phase 3 studies in adults with uncomplicated influenza (often called the “flu”). The two studies enrolled 2,021 patients in participating clinics and practices […]
BOSTON, Jan. 16, 2014 — MediVector, Inc. today announced the enrollment of its first patient in the United States in one of two FAVOR favipiravir Phase 3 studies in adults with uncomplicated influenza. This multi-center, double-blind, placebo-controlled study is expected to enroll over 1,000 patients in participating clinics and practices in North, Central, and South America. “The […]